Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
Combination of Toripalimab and JS004 Therapy for ccRCC
- Conditions
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT06690697
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
CARE1 Pragmatic Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1250
- Registration Number
- NCT06364631
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06279403
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06211114
- Locations
- 🇨🇳
Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06161558
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 17
- Registration Number
- NCT05969496
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT05949632
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centrewester, Glasgow, United Kingdom
🇬🇧Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧St Bartholomew'S Hospital, London, United Kingdom
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Lynkcell Europe
- Target Recruit Count
- 30
- Registration Number
- NCT05904730
- Locations
- 🇺🇦
Trials TEAM, Kyiv, Ukraine
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 118
- Registration Number
- NCT05817903
- Locations
- 🇮🇹
Casa Di Cura La Maddalena S.P.A., Palermo, Italy
🇮🇹Ospedale di Belcolle, Viterbo, Italy
🇮🇹ASST degli Spedali Civili di Brescia, Brescia, Italy
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Hao Zeng
- Target Recruit Count
- 33
- Registration Number
- NCT05808608
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.